NAD+ vs Selank — Research Comparison

NAD+ is a coenzyme present in every cell you have. Selank is a synthetic sequence that has never existed in any organism. The comparison is usually run on effects; the more informative axis is that one is framed as replacement and the other as introduction, and those require different proof.

Proxiva Analytical DeskCertificate review, purity and identity testing

Two different kinds of claim

The useful distinction between these compounds is not what they are associated with. It is the logical structure of what is being claimed for each, and that structure determines what evidence would settle the matter.

NAD+ is endogenous. Every cell contains it, uses it continuously in redox reactions, and maintains it through synthesis and salvage pathways. A claim about supplementing it is therefore a replacement claim, and replacement claims carry an unusual burden: they must establish that a meaningful deficit exists in the first place, and that what is administered corrects it. Neither half is automatic.

Selank is synthetic. It derives from a fragment of an endogenous peptide but was modified to alter its properties, and the modified sequence occurs nowhere in nature. Nothing can be deficient in it. A claim about it is therefore an introduction claim, which needs only to establish that administering it produces an effect — a lower bar in structure, though not necessarily easier to meet.

This is why arguments about the two so often talk past each other. A criticism that lands hard against a replacement claim may be irrelevant to an introduction claim, and vice versa.

The problem specific to the endogenous compound

For NAD+ the central open question is narrower than most discussion suggests, and it is worth stating precisely because the discussion rarely does.

That NAD+ is essential is not in question. That its availability constrains a range of cellular processes is not in question either. Those points are settled biochemistry and no serious source disputes them.

What is genuinely unresolved is whether administering the molecule raises the pool inside cells where it would need to be raised to matter. The molecule is large and charged, cells maintain their own internal concentrations through dedicated machinery, and material in circulation is not automatically material inside a cell. This is a distribution question, not a question about whether the compound is important.

The distinction matters because it is routinely elided. Evidence that NAD+ is essential is presented as though it were evidence that supplementing it works, and those are separate claims requiring separate support. A source that establishes the first and concludes the second has skipped the step where the argument is actually contested.

The same structural question applies to other endogenous compounds sold in this category. Glutathione faces a closely related version of it, and for similar reasons — an essential molecule whose importance is undisputed and whose supplementation route is not.

The problem specific to the synthetic one

Selank’s difficulty is not structural in the same way. Being synthetic, it faces no deficiency question at all: it is either doing something or it is not, and that is straightforwardly testable in principle.

The obstacle is practical. A substantial portion of the primary work exists in Russian-language publications, conducted within a research and regulatory tradition that differs in its conventions from the one most English-language readers are calibrated to. That does not make the work unreliable. It makes it difficult to assess without reading it directly, and most secondary accounts have not.

The observable consequence is a literature that recirculates. English-language descriptions frequently cite one another rather than the underlying studies, and confident summaries accumulate distance from anything that was actually measured. A claim can be repeated widely and still trace back to very little.

The check that helps is genealogical rather than technical: follow a claim backwards and count the steps to a primary source. Claims that reach one in a step or two are worth something. Claims that dissolve into other summaries are worth considerably less regardless of how often they appear. The same test applies to Semax, which shares Selank’s origins and its citation problem almost exactly.

Procedure: what to establish before either arrives

The design decisions that determine whether a result will be interpretable are made before any material is ordered — and the first of them is the one most often skipped entirely.

Establish which kind of claim the work is testing, because replacement and introduction claims require structurally different designs. A replacement claim needs a baseline against which restoration can be measured, and without one the experiment cannot distinguish a compound that failed to act from a compound that acted on a deficit which was never present. An introduction claim needs a control rather than a baseline, since nothing is being restored and the question is simply whether an effect occurs at all.

For the endogenous compound, decide in advance how the intracellular pool will be assessed — or acknowledge openly that it will not be. This matters more than any other decision in the design, because circulating material and intracellular material are different quantities, and an experiment that measures neither cannot separate an ineffective compound from an effective one that never reached the compartment where it would have mattered.

For the synthetic compound the burden shifts to provenance rather than measurement. Trace the specific claim being tested back to a primary source before building a design around it, and count the intermediate steps — a claim that reaches a measurement in one or two moves can carry a design, while one that dissolves into a chain of summaries cannot, however widely it circulates.

The material checks are ordinary and apply to both: a certificate matched to the batch in hand rather than to the product line, identity established by mass spectrometry before purity is read by chromatography, and quantity confirmed separately — since neither identity nor purity establishes how much material the vial actually contains.

It is worth stating plainly what happens when the first decision is skipped, because the failure is silent rather than obvious. The work proceeds, data accumulates, and the result appears to mean something — but the design was never capable of distinguishing between the two explanations that matter, and no amount of subsequent analysis can recover a distinction that the experiment did not build in.

Verification differences

Selank is a short peptide and among the more straightforward syntheses in this catalogue. Few couplings means few opportunities to produce a nearly-correct product, so the realistic risk is a wrong molecule or a short fill rather than a subtly defective one. This places it alongside KPV and Epithalon in difficulty.

NAD+ is not a peptide and is not characterised the same way. It is a nucleotide-derived coenzyme, and the relevant analysis establishes chemical identity and purity by methods appropriate to a small molecule rather than to a synthesised chain. A certificate presenting it in peptide terms has been written by someone applying a template rather than analysing the material.

That is a useful signal in itself. Certificates that do not match the chemistry of what they describe indicate a supplier generating documents rather than commissioning analysis, and the observation generalises well beyond these two compounds.

Handling

Both arrive lyophilised, both are stable in that form under refrigeration, and both shorten substantially once reconstituted with bacteriostatic water where repeated withdrawal is intended.

Direct the diluent against the vial wall and allow dissolution to proceed without agitation. Avoid unnecessary temperature cycling — repeated warming and cooling degrades material more reliably than any single handling error and is the least likely to be noticed, since nothing about it looks like a mistake at the time.

The quantities differ substantially between them, and the volumes required to reach workable concentrations differ accordingly. Choose the volume for the resolution of the measurement rather than for convenience, since a solution too concentrated to measure accurately has cost more than the diluent would have.

What neither literature establishes

No study has compared these two, and none would be expected to. A coenzyme central to cellular redox chemistry and a synthetic peptide with a neurological association do not compete for any application.

The evidence bases fail in opposite directions, which is the most useful thing to take from the pairing. NAD+ has abundant, accessible, high-quality work establishing its importance and a genuinely unresolved question about whether supplementation reaches the compartment that matters. Selank has a plausible mechanism, a modest literature, and an access problem that makes the literature difficult to weigh from outside.

One is well evidenced on the wrong question. The other may be adequately evidenced on the right one, and it is hard to tell. Neither of those is the same as being well supported, and the distinction is worth keeping when reading confident claims about either.

Frequently asked questions

Research use only. All products referenced on this page are sold strictly for laboratory and research purposes. They are not drugs, foods, cosmetics, or medical devices, and they are not intended to diagnose, treat, cure, or prevent any disease. They are not for human or veterinary consumption. Handling should be performed only by qualified individuals in an appropriate laboratory setting.